You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


European Commission approves Nucula treatment in three diseases

GlaxoSmithKline (GSK) announced that the European Commission has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5) for use in three additional eosinophil-driven diseases.